Schmid P, Pavek P, Klein W
Z Kardiol. 1979 Feb;68(2):89-92.
15 patients with obstructive hypertrophic cardiomyopathy were studied by m-mode echocardiography and 9 of them also by left heart catheterism before and after 10 mg Verpamil. The following results were obtained: 1. The systolic anterior movement (SAM) of the mitral valve was reduced (p less than 0.005), 2. the enddiastolic and endsystolic diameter were increased (p less than 0.02 and 0.05 respectively), 3. the EF-slope remained unchanged. 4. The left ventricular systolic pressure was reduced (p less than 0.025) and the gradient diminished from an average value of 58 to 34 mmHg (p less than 0.02), 5. heart rate and left ventricular enddiastolic pressure remained constant. The results of this acute study suggest a beneficial effect of Verpamil in patients with hypertrophic obstructive cardiomyopathy.
对15例梗阻性肥厚型心肌病患者进行了M型超声心动图研究，其中9例在服用10毫克维拉帕米前后还进行了左心导管检查。获得了以下结果：1.二尖瓣收缩期前向运动（SAM）减少（p<0.005）；2.舒张末期和收缩末期直径增加（分别为p<0.02和0.05）；3.EF斜率保持不变；4.左心室收缩压降低（p<0.025），压力阶差从平均58毫米汞柱降至34毫米汞柱（p<0.02）；5.心率和左心室舒张末期压力保持不变。这项急性研究的结果表明维拉帕米对肥厚性梗阻性心肌病患者有有益作用。
